ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 258

Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus

Geyanne Lui1, Mangala Rajan 1, Lisa Kern 1, Laura Pinheiro 1, Monika Safford 1, Jeffrey Curtis 2 and Iris Navarro-Millan 1, 1Weill Cornell Medicine, New York, 2University of Alabama at Birmingham, Birmingham, AL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: clinical practice guidelines and health disparities, health services utilization, Medicare, Rheumatoid arthritis (RA)

Session Information

Date: Sunday, November 10, 2019

Title: Health Services Research Poster I – ACR/ARP

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65 years of age are complex patients with heavy healthcare use. These young disabled patients cost 31% more than older Medicare patients, but we do not know whether they are receiving the basic standards of diabetes care given their disability and complexities related to also having RA. Our purpose was to assess the standard of care for diabetes measured by health services utilization in patients under 65 years of age who are disabled with RA and DM by race and ethnicity.

Methods: We conducted a longitudinal analysis from 2010– 2014 of patients who were beneficiaries of the SSDI with both RA and DM. RA was defined in 2010 as either 1) two RA diagnoses (ICD9-714.xx) by a rheumatologist between 7 and 365 days apart; OR 2) one RA diagnosis by a rheumatologist and at least 1 prescription for a disease modifying anti-rheumatic drug. DM was defined as one diagnosis from any physician (ICD-9 250.xx) in 2010. Patients were followed for 4 years (2011 – 2014) and outcomes were the testing and visit standards defined by the 2010 American Diabetes Association. We used Poisson models to adjust for age, gender, and Charlson-Deyo Comorbidity Index and examined the differences between racial/ethnic groups.

Results: In 2010, there were 5,380 patients under the age of 65 disabled with RA and DM receiving SSDI benefits. The cohort was 78% female and 61% had 5 or more comorbidities. These patients had high health services utilization with a mean number of visits to the doctor of about 18 visits a year (Table 1). More than half (53.5%) of all patients did not receive a foot exam and almost a quarter (23.3%) did not receive an eye exam in 2011-2014. After multivariable adjustment, Hispanic patients had a statistically significant higher annual mean of testing (HbA1c 2.39 vs 2.19, urine albuminuria 2.8 vs 2.28, and lipid 1.96 vs 1.67) than White patients in 2011-2014 (Table 2). Both Hispanic and Black patients had a higher annual mean of eye exams (1.16 and 1.03, respectively, vs 0.88) but lower annual mean of foot exams (1.01 and 1.04, respectively, vs 1.18) than the White patients.

Conclusion: Disabled patients with RA and DM had high utilization of health services and received most of the recommended standard of care for diabetes, which was similar across all racial/ethnic groups. The exception was for eye exams, which was lower among Whites. However, there was low utilization of specialty services related to DM care such as ophthalmology evaluations or foot exams by any physician.


ACR_2019_abstract_SoC_table 1


ACR_2019_abstract_SoC_table 2


Disclosure: G. Lui, None; M. Rajan, None; L. Kern, None; L. Pinheiro, None; M. Safford, Amgen, 2, 9; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; I. Navarro-Millan, None.

To cite this abstract in AMA style:

Lui G, Rajan M, Kern L, Pinheiro L, Safford M, Curtis J, Navarro-Millan I. Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/health-services-utilization-as-recommended-by-the-american-diabetes-association-among-middle-aged-patients-disabled-with-rheumatoid-arthritis-and-diabetes-mellitus/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-services-utilization-as-recommended-by-the-american-diabetes-association-among-middle-aged-patients-disabled-with-rheumatoid-arthritis-and-diabetes-mellitus/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology